You are here

Article Text

Article menu
Download PDFPDF
Letter
Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis
  1. D C Baumgart,
  2. A Sturm,
  3. B Wiedenmann,
  4. A U Dignass
  1. Department of Medicine, Division of Hepatology and Gastroenterology, Charité Medical Centre-Virchow Hospital, Medical School of the Humboldt-University of Berlin, Berlin, Germany
  1. Correspondence to:
    Professor A U Dignass
    Charité Medical Centre-Virchow Hospital, Medical School of the Humboldt-University, Department of Medicine, Division of Hepatology and Gastroenterology, D-13344 Berlin, Germany; axel.dignasscharite.de

https://doi.org/10.1136/gut.2005.078972

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Tacrolimus is currently approved only in patients receiving allogeneic liver or kidney transplants.1 We and others have demonstrated its successful use in refractory colitis.2,3 Here we report the first patient who was successfully maintained in remission during pregnancy and delivered a healthy baby.

    Our patient was diagnosed with ulcerative colitis at the age of 25 years. Her first baby was delivered by Caesarean section prematurely at 29 weeks’ gestation. Frequent flare ups of her pancolitis required repeated steroid rescue and she was soon started on azathioprine. Unfortunately, she was unable to tolerate purine analogues due to heterozygous thiopurine methyltransferase deficiency causing severe pancytopenia and life threatening sepsis.

    Discussing the remaining therapeutic options, the patient refused proctocolectomy and ileoanal pouch anastomosis and chose a trial …

    View Full Text